Is it time to routinely incorporate MRD into practice?

Research output: Contribution to journalReview article

1 Scopus citations


Interest in detecting minimal/measurable residual disease (MRD) in acute myeloid leukemia (AML) has been increasing, but numerous issues need to be addressed if MRD assessment is to be routinely incorporated into practice. Assays, their reliability, standardization, and availability all must be considered, and a strategy developed to eradicate residual leukemia. This paper reviews some issues surrounding the routine incorporation of MRD assessment into practice.

Original languageEnglish (US)
Pages (from-to)396-400
Number of pages5
JournalBest Practice and Research: Clinical Haematology
Issue number4
StatePublished - Dec 2018


  • AML
  • Acute myeloid leukemia
  • Assay
  • MFC
  • MRD
  • Minimal/measurable residual disease
  • Multi-parameter flow cytometry
  • NGS
  • Next-generation sequencing
  • RT-PCR
  • Reverse-transcriptase-polymerase-chain reaction

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Is it time to routinely incorporate MRD into practice?'. Together they form a unique fingerprint.

  • Cite this